Search
Tulrampator
go.drugbank.com/drugs/DB16344InvestigationalTulrampator is under investigation in clinical trial NCT02626572 (Efficacy and Safety of 3 Doses of S47445 Versus Placebo in Patients With Alzheimer's Disease at Mild to Moderate Stages With Depressive
Ichorcumab
go.drugbank.com/drugs/DB18930InvestigationalIchorcumab is under investigation in clinical trial NCT03251482 (A Study to Evaluate the Safety and Efficacy of Intravenous JNJ-64179375 Versus Oral Apixaban in Participants Undergoing Elective Total Knee
Rizedisben
go.drugbank.com/drugs/DB21610InvestigationalRizedisben is a small molecule drug. Rizedisben is under investigation in clinical trial NCT04983862 (Fluorescent Imaging of Nerves with Illuminare-1 During Surgery).
Dalcinonacog alfa
go.drugbank.com/drugs/DB17707InvestigationalDalcinonacog alfa is a recombinant human factor IX (FIX) variant. It is being investigated for the treatment of hemophilia B.[A259058]
TTX-MC138
go.drugbank.com/drugs/DB18628InvestigationalTTX-MC138 is an antisense oligonucleotide targeting miR-10b.[L48335] It is under investigation for the treatment of various metastatic cancers.
TOP-1288
go.drugbank.com/drugs/DB14839InvestigationalTOP-1288 is under investigation in clinical trial NCT02888379 (Phase 2a Study to Evaluate the Safety/Tolerability and Efficacy of TOP1288 200 mg Rectal Solution Once Daily for 4 Weeks in Ulcerative Colitis
Rilematovir
go.drugbank.com/drugs/DB15672InvestigationalRilematovir is under investigation in clinical trial NCT04056611 (Effects of JNJ-53718678 in Adult and Adolescent Participants Who Had a Hematopoietic Stem Cell Transplantation and Who Are Infected With
Nivatrotamab
go.drugbank.com/drugs/DB16654InvestigationalNivatrotamab is under investigation in clinical trial NCT03860207 (Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3f8-bsab) in Patients With Relapsed/refractory Neuroblastoma,
IMM-0306
go.drugbank.com/drugs/DB19309InvestigationalIMM-0306 (bispecific antibody-trap selectively targeting cd47 and cd20) is under investigation in clinical trial NCT05805943 (Study of IMM0306 in Patients With Relapsed or Refractory Cd20-positive B-cell
ARCoV
go.drugbank.com/drugs/DB15855ExperimentalIt is the first COVID-19 mRNA vaccine to be approved for clinical trials in China, and was co-developed by Abogen Biosciences, Walvax Biotechnolgoy Co., Ltd. and the People’s Liberation Army (PLA) Academy … Preclinical studies in mice and non-human primates has shown that intramuscular administration of ARCoV elicited a Th1-biased cellular response and robust antibodies against SARS-CoV-2[A220048].